Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein

ABSTRACT

Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpre S1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.

CROSS-REFERENCE

This application claims priority to U.S. Provisional Patent ApplicationSer. No. 62/587051 filed Nov. 16, 2017, incorporated by reference hereinin its entirety.

STATEMENT OF GOVERNMENT RIGHTS

This disclosure was made with government support under Grant No.HR0011-11-2-0007, awarded by the Defense Advanced Research ProjectsAgency. The government has certain rights in the disclosure.

BACKGROUND OF THE DISCLOSURE

In spite of the availability of prophylactic Hepatitis B virus (HBV)vaccines, HBV infection remains a very significant global health problemin both industrialized and developing nations; it is second only totobacco as a cause of cancer. There is a clear unmet need for atherapeutic HBV vaccine for patients chronically infected with HBV(CHB). 10-30% of those vaccinated with marketed HBV vaccines do notrespond either due to genetic factors, or non-compliance (failure toreturn for a series of 3 vaccinations). Only 37% of individualsvaccinated once with a licensed HBV vaccine are protected; even afterthree vaccinations, which are difficult to achieve, many people do notrespond effectively. There is no effective vaccine for the 400 millionpeople chronically infected with HBV, including asymptomatic HBVcarriers. The drugs currently used to treat CHB patients areproblematic. Sustained antiviral responses are rarely achieved and thecurrently available therapies can lead to viral resistance and produceside effects in many CHB patients.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 . Schematic design of the G28-8LH-scAb-PreS1-S2-His protein.

FIG. 2 . Characterization of recombinant G28-8LH-scAb-PreS1-S2-His .G28-8LH-scAb-PreS1-S2-His was transiently expressed in CHO cells.Culture supernatant was passed over a Ni2+ affinity chromatographycolumn. Bound G28-8LH-scAb-PreS1-S2-His was eluted with imidazole.Eluted protein (E) was characterized by reducing SDS-PAGE and westernblotting using an anti-6×-His antibody.

FIG. 3 . Binding of recombinant G28-8LH-scAb-PreS1-S2-His to human Bcells. Direct binding to human gated CD20+ tonsillar B cells using aFITC-anti-His monoclonal antibody (bold black line). Second step only(light black line).

FIG. 4 . Recombinant G28-8LH-scAb-PreS1-S2-His activates human B cells.Sheep erythrocyte-binding negative blood mononuclear cells enriched forB cells were incubated at 37 C for 24 hours either with media only(light black line), or with G28-8LH-scAb-PreS1-S2-His (bold black line).Samples were gated for CD20+ cells (Pacific blue-anti-CD20) and levelsof CD40 expression measured as an indication of activation using flowcytometry. Graph shows CD40 expression of gated CD20⁺ B cells.

FIG. 5 . Immune responses in macaques immunized and boosted withrecombinant G28-8LH-scAb-PreS1-S2-His recombinant protein(CD180-HBV-preS1/S2). Groups of cynomolgus macaques (Macacafascicularis) (N=3) were vaccinated subcutaneously with either: 1) 300μg of G28-8LH-scAb-PreS1-S2-His (CD180-HBV-PreS1/S2, black circles); or2) 300 μg of G28-8LH-scAb-PreS1-S2-His (aCD180-HBV-preS1/S2) plus 0.5 mlAddavax™ (open squares). Animals were vaccinated on days 0 and 30, andserum and heparinized blood samples were obtained on days 0, 7, 14, 30after primary immunization and days 7, 14, and 30 after secondaryimmunization. (A) HBV-PreS1-specific IgG antibody levels detected usingELISA. Mean optical densities (O.D.) at each time point ±SEM areindicated. (B) HBsAg-specific IFN-γ-producing T cells detected byELIspot assays. Statistical comparisons between the two groups for eachassay were assessed at each timepoint using unpaired t test on sampleswith equal standard deviation. Significant differences are indicated:*P=0.01, ***P=0.006. For all other timepoints, there was no significantdifference in mean responses between the groups.

FIG. 6 . G28-8LH-scAb-PreS1-S2-His recombinant protein vaccine inducedneutralizing antibodies (Abs) that block the production of HBV cccDNA inHBV infected liver cells. Cynomolgus macaques (Macaca fascicularis,N=3/group) received a priming and booster as described in FIG. 11 witheither 300 ug G28-8LH-scAb-PreS1-S2-His (A57, A59 and A60) or 300 μgG28-8LH-scAb-PreS1-S2-His co-formulated with 100 μg of the commercialadjuvant, AddaVax™ (A55, A58 and A68, indicated by * in figure). Seraobtained 2 weeks after the second immunization were evaluated forneutralizing antibody activity. (A) The scheme illustrates the treatmentschedule with HBV inoculum (10³ Geq per cell) and serum samples(Neutralizing Ab). HepG2-hNTCP cells were treated with pre-bleed serumat a 1:1000 dilution (D) or immune sera from macaques at !:300, 1:1000or 1:3000 dilution for 16 hours after the time of the HBV inoculation.At 1 day post infection (dpi), the mediums containing 2.5% DMSO werereplaced. The cccDNAs were extracted at 3 dpi, and analyzed by real-timePCR. (B) HepG2-hNTCP cells infected with HBV (10³ Geq/cell) were treatedwith sera as indicated (1:300 D=dilution of the original serum stock to1/300 as vol/vol, 1:1000 D=dilution of the original serum stock to1/1000 as vol/vol, 1:3000 D=dilution of the original serum stock to1/3000 as vol/vol). Pre-bleed serums (1/1000 dilution (vol/vol)) wereincluded as a control. At 3dpi, cccDNAs were analyzed by real-time PCR.Following digestion of T5 exonuclease, cccDNA was specificallyquantified using specific primers.

cccDNA was normalized as a ratio to mitochondrial DNA. Representativedata are shown with quantification (means ±standard deviation) (n=2).

DETAILED DESCRIPTION OF THE DISCLOSURE

All references cited are herein incorporated by reference in theirentirety. Within this application, unless otherwise stated, thetechniques utilized may be found in any of several well-known referencessuch as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989,Cold Spring Harbor Laboratory Press), Gene Expression Technology(Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. AcademicPress, San Diego, Calif.), “Guide to Protein Purification” in Methods inEnzymology (M. P. Deutshcer, ed., (1990) Academic Press, Inc.); PCRProtocols: A Guide to Methods and Applications (Innis, et al. 1990.Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual ofBasic Technique, 2^(nd) Ed. (R. I. Freshney. 1987. Liss, Inc. New York,N.Y.), Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J.Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998Catalog (Ambion, Austin, Tex.).

As used herein, the singular forms “a”, “an” and “the” include pluralreferents unless the context clearly dictates otherwise. “And” as usedherein is interchangeably used with “or” unless expressly statedotherwise.

As used herein, the amino acid residues are abbreviated as follows:alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine(Arg; R), cysteine (Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q),glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu;L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F),proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp;W), tyrosine (Tyr; Y), and valine (Val; V).

All embodiments of any aspect of the disclosure can be used incombination, unless the context clearly dictates otherwise.

In a first aspect, the present disclosure provides compositions,comprising:

(a) a CD180 binding ligand; and

(b) Hepatitis B virus pre-S1 and/or pre-S2 regions of the HBV envelopeprotein (HBVpreS1-S2Ag), S-HBsAg, or antigenic fragments or mutantsthereof, attached to the CD180 binding ligand.

The compositions of the disclosure can be used, for example, to induceprophylactic responses in individuals at risk of HBV infection, andtherapeutic responses in already infected individuals and inimmunodeficient individuals who do not respond well to standardvaccines. The present disclosure is highly significant because itprovides a therapeutic vaccine for one of the major causes of cancer andliver disease in the world: hepatitis B virus

(HBV). HBV infection is a serious global public health problem in bothindustrialized and developing nations. 10-30 million people worldwidebecome infected with HBV each year, and more than 2 billion peopleworldwide have been infected with HBV. Significantly, the ability ofunvaccinated individuals to mount effective immune responses against HBVis correlated with age. Infants and young children are particularly atrisk, as 90% of infants and up to 50% of young children infected withHBV ultimately develop chronic infections. About 400 million arechronically infected with HBV (CHB), and in the USA there areapproximately 1.4 million CHB infected people⁵. In the USA theprevalence of HBV while dropping in children, has changed little inadults¹¹ such that the burden of chronic hepatitis B among adultsremains large; in some groups it is as high as 1%. An estimated 1million people die each year from hepatitis and its complications,including about 5,000 people in the US. Of the 5000 persons in theUnited States who die each year from HBV related conditions, 300 diefrom fulminant hepatitis; 3-4000, from cirrhosis; and 600-1000, fromprimary hepatocellular carcinoma (HCC). In the US, approximately 400health care workers are infected each year and are at risk from dyingfrom HBV-related disease¹⁶.

The CD180 binding ligand may be any molecule that binds directly toCD180 present in the surface of B cells, macrophages, or dendriticcells. In various non-limiting embodiments, the CD180 binding ligand maybe a peptide mimetic or an antibody.

In a particular embodiment, the CD180 binding ligand is an antibody orantibody fragment. As used herein, “antibody” includes reference to fulllength and functional fragments of any of the following: animmunoglobulin molecule immunologically reactive with human CD180(preferably selective for CD180), genetically engineered forms such aschimeric antibodies (e.g., humanized murine antibodies) andheteroconjugate antibodies (e.g., bispecific antibodies), fullyhumanized antibodies, human antibodies, single chain Fv fragments(scFv), bivalent or bispecific molecules, diabodies, triabodies, andtetrabodies, single domain molecules such as VH and VL that are capableof specifically binding to an epitope of an antigen, and camelids.Fragments with antigen-binding activity include, but are not limited to,Fab′, F(ab′)₂, Fab, Fv and rigG and includes monoclonal antibodies.Various isotypes of antibodies exist, for example IgG1, IgG2, IgG3,IgG4, and other Ig, e.g., IgM, IgA, IgE isotypes. The term alsoincludes. Bivalent and bispecific molecules are described in, e.g.,Kostelny et al. (1992) J Immunol 148:1547, Pack and Pluckthun (1992)Biochemistry 31:1579, Hollinger et al., 1993, supra, Gruber et al.(1994) J Immunol:5368, Zhu et al. (1997) Protein Sci 6:781, Hu et al.(1996) Cancer Res. 56:3055, Adams et al. (1993) Cancer Res. 53:4026, andMcCartney, et al. (1995) Protein Eng. 8:301. Various antigen bindingdomain-fusion proteins are also disclosed, e.g., in US patentapplication Nos. 2003/0118592 and 2003/0133939, and are encompassedwithin the term “antibody” as used in this application.

An antibody immunologically reactive with human CD180 can be generatedby recombinant methods such as selection of libraries of recombinantantibodies in phage or similar vectors, see, e.g., Huse et al., Science246:1275-1281 (1989); Ward et al., Nature 341:544-546 (1989); andVaughan et al., Nature Biotech. 14:309-314 (1996), or by immunizing ananimal with the antigen or with DNA encoding the antigen.

In one embodiment, the CD180 binding ligand comprises a single chain(sc) recombinant protein, wherein the sc recombinant protein comprises:

(i) a variable heavy (VH) chain region of an anti-CD180 antibody; and

(ii) a variable light (VL) chain region of an anti-CD180 antibody.

In one embodiment, the CD180 binding ligand comprises a single domain(sd) recombinant protein, wherein the sd recombinant protein comprises avariable heavy (VHH) chain region of an anti-CD180 antibody derived froma camelid species.

The VH and VL chain regions may be from an anti-human CD180 antibody,such as an anti-human CD180 monoclonal antibody. Exemplary commerciallyavailable CD180 anti-human monoclonal antibodies from which the VH andVL chains may be used include, but are not limited to, those sold by AbDSerotec™ (“MHR73-11”), BD Biosciences, Thermo Scientific, Sigma Aldrich,etc.), (“G28-8”), and LifeSpan™ (“200.1”). In one embodiment, the singlechain recombinant protein does not include any other immunoglobulindomains (i.e.: a single chain variable fragment (scFv)). In analternative embodiment, the single chain recombinant protein furthercomprises: CH2 and CH3 domains from an immunoglobulin (Ig), such as ahuman Ig, or functional mutants thereof, wherein the CH2 and CH3 domainsare located C-terminal to the VH and VL domains. The CH2 and CH3 domainsmay be from any immunoglobulin as deemed appropriate for an intended useof the composition, including but not limited to IgA1, IgA2, IgG1, IgG2,IgG3, IgG4, IgM, etc. In a particular embodiment, the sc recombinantprotein comprises CH2 and CH3 domains from IgG1, such as human IgG1, orfunctional mutants thereof. In a particular embodiment, such “functionalmutants” comprise CH2 and/or CH3 domains that have impaired binding tohuman or animal Fc receptor FcγRilb and/or to human or animal complementproteins (J Biol Chem 276: 6591-6604). The Fc domain of the recombinantmolecules is an altered human IgG1 Fc domain with three amino acidchanges (P238S, P331S, K322S) that reduce the binding of the molecule toFc receptors and C1q. Other amino acid substitutions that can reducebinding of human IgG1 to various Fc receptors include but are notlimited to E233P, L234V, L235A, G236 deletion, P238A, D265A, N297A,A327Q, and P329A. Substitutions at these amino acids reduce binding toall FcγR. Substitutions at D270A, Q295A, or A327S reduce binding toFcγRII and FcγRIIIA. Substitutions at S239A, E269A, E293A, Y296F, V303A,A327G, K338A, and D376A reduce binding to FcγRIIIA but not FcγRII. Acombination of two of more of these substitutions can be engineered inthe Fc domains of human IgG1 to achieve the desired effects oninhibiting Fc-FcγR interaction between CD180 targeted vaccines and FcgRexpressing cells. Similarly, modifying the glycosylation profile ofhuman IgG1, for example, substitution of the N-linked glycosylation siteat Asn-297 of human IgG1, eliminates N-linked glycosylation of humanIgG1, thereby eliminating its binding to Fc receptors as well ascomplement fixation functions (John S. Axford (ed.), Glycobiology andMedicine, 27-43; 2005 Springer).

In these various embodiments of the compositions of the disclosure, theVL chain region may be located N-terminal to the VH chain region, or theVH chain region may be located N-terminal to the VL chain region, asdisclosed in the examples that follow.

In one embodiment, the CD180-antibody comprises mAb G28-8, which iscommercially available from a number of sources, (BD Biosciences, ThermoScientific, Sigma Aldrich, etc.), a F(ab′)2 fragment of mAb G28-8, or asingle chain recombinant protein having the VL and VH domains of G28-8,and optionally further comprising CH2 and CH3 domains from animmunoglobulin (Ig), such as a human Ig, or functional mutants thereof.

In another embodiment, the CD180 binding ligand competes for binding toCD180 with monoclonal antibody G28-8. As used herein, competing CD180binding ligands are those binding proteins that bind to about,substantially or essentially the same, or even the same, epitope asG28-8. Competing binding proteins, such as competing antibodies orderivatives thereof, include binding proteins with overlapping epitopespecificities. Competing binding proteins are thus able to effectivelycompete with G28-8 antibody, such as the G28-8 antibody obtained fromThermo Scientific (the “reference antibody”) for binding to CD180. Abinding protein that competes with the reference G28-8 antibody forbinding to CD180 will be able to effectively or significantly reduce(i.e.: reduce by at least 10%; preferably by at least 20%, 30%, 40%,50%, 60%, 70%, 80%, 90%, or more) reference G28-8 antibody binding toCD180, as evidenced by a reduction in bound label. In one embodiment,the reference G28-8 antibody is pre-mixed with varying amounts of thetest binding proteins (e.g., 1:10, 1:100 or 1:1000) for a period of timeprior to applying to a CD180 composition. In other embodiments, thereference G28-8 antibody and varying amounts of test binding proteinscan simply be admixed during exposure to the CD180 composition. By usingspecies or isotype secondary antibodies one will be able to detect onlythe bound reference G28-8 antibody, the binding of which will be reducedby the presence of a test binding protein that “competes” for binding.Examples of detection of such binding events are provided herein. As theidentification of competing binding proteins is determined in comparisonto the reference G28-8 antibody, it will be understood that actuallydetermining the epitope to which the binding proteins bind is not in anyway required in order to identify a competing binding proteins. However,epitope mapping can be performed, if desired.

In another embodiment, the CD180 binding ligand activatesantigen-presenting cells, e.g., to increase expression of CD40, as shownin the examples that follow.

The compositions of the disclosure comprise a Hepatitis B virus preS1and/or pre-S2 region of the envelope antigen (HBVpreS1/S2Ag), anS-HBsAg, or antigenic fragments or mutants thereof (collectivelyreferred to as HBVpreS1/S2Ag or S-HBsAg) attached to the CD180 bindingligand. Thus, the compositions may comprise one or more HBVpreS1/S2Agsand/or S-HBsAgs. In all embodiments, one or more copies ofHBVpreS1/S2Ags and/or S-HBsAgs may be present at the N-terminus or theC-terminus of the single chain recombinant protein. PreSi and PreS2 arepresent in HBV surface antigens L-HBsAg and M-HBsAg and thus theHBVpreS1/S2Ag may comprise isolated PreS1 and/or PreS2, or may compriseHBV L-HBsAg or M-HBsAg. The HBVpreS1/S2Ag, L-HBsAg, M-HBsAg, and S-HBsAgmay be from any HBV genotype, serotype, variant, mutant, or isolate.

In various embodiments, the composition may comprise an HBVpreS1/S2Ag orS-HBsAg at least 90% identical over the length of the amino acidsequence of one or more of the following:

pres1/preS2 (SEQ ID NO: 1)MGGWSSKPRQ GMGTNLSVPN PLGFFPDHQL DPAFGANSNN PDWDFNPNKD HWPEANQVGAGAFGPGFTPP HGGLLGWSPQ AQGILTTLPA APPPASTNRQ SGRQPTPISP PLRDSHPQAMQWNSTTFHQA LLDPRVRGLY FPAGGSSSGT VNPVPTTASP ISSIFSRTGD PAPN preS1(SEQ ID NO: 2)MGGWSSKPRQ GMGTNLSVPN PLGFFPDHQL DPAFGANSNN PDWDFNPNKD HWPEANQVGAGAFGPGFTPP HGGLLGWSPQ AQGILTTLPA APPPASTNRQ SGRQPTPI preS2(SEQ ID NO: 3)SPPLRDSHPQA MQWNSTTFHQ ALLDPRVRGL YFPAGGSSSG TVNPVPTTAS PISSIFSRTG DPAPN  L-HBsAg (SEQ ID NO: 4)MGGWSSKPRQ GMGTNLSVPN PLGFFPDHQL DPAFGANSNN PDWDFNPNKD HWPEANQVGAGAFGPGFTPP HGGLLGWSPQ AQGILTTLPA APPPASTNRQ SGRQPTPISP PLRDSHPQAMQWNSTTFHQA LLDPRVRGLY FPAGGSSSGT VNPVPTTASP ISSIFSRTGD PAPNMESTTSGFLGPLLVLQ AGFFLLTRIL TIPQSLDSWW TSLNFLGGAP TCPGQNSQSP TSNHSPTSCPPTCPGYRWMC LRRFIIFLFI LLLCLIFLLV LLDYQGMLPV CPLLPGTSTT STGPCRTCTIPAQGTSMFPS CCCTKPSDGN CTCIPIPSSW AFARFLWEWA SVRFSWLSLL VPFVQWFVGLSPTVWLSAIW MMWYWGPSLY NILSPFLPLL PIFFCLWVYI M-HBsAg (SEQ ID NO: 5)PPLRDSHPQA MQWNSTTFHQ ALLDPRVRGL YFPAGGSSSG TVNPVPTTAS PISSIFSRTGDPAPNMESTT SGFLGPLLVL QAGFFLLTRI LTIPQSLDSW WTSLNFLGGA PTCPGQNSQSPTSNHSPTSC PPTCPGYRWM CLRRFIIFLF ILLLCLIFLL VLLDYQCMLP VCPLLPGTSTTSTGPCRTCT IPAQGTSMFP SCCCTKPSDG NCTCIPIPSS WAFARFLWEW ASVRFSWLSLLVPFVQWFVG LSPTVWLSAI WMMWYWGPSL YNILSPFLPL LPIFFCLWVY I  S-HBsAg(SEQ ID NO: 6)MESTTSGFLG PLLVLQAGFF LLTRILTIPQ SLDSWWTSLN FLGGAPTCPG QNSQSPTSNHSPTSCPPTCP GYRWMCLRRF IIFLFILLLC LIFLLVLLDY QGMLPVCPLL PGTSTTSTGPCRTCTIPAQG TSMFPSCCCT KPSDGNCTCI PIPSSWAFAR FLWEWASVRF SWLSLLVPFVQWFVGLSPTV WLSAIWMMWY WGPSLYNILS PFLPLLPIFF CLWVYIP31873 Hepatitis B virus genotype A1 subtype adw2 (isolateSouthern-Africa/Cai)

Pres1 (SEQ ID NO: 7) MGGWSAKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANQVGVGAFGPGFTPPHGGLLGWSSQ AQGTLHTVPAVPPPASTNRQTGRQPTPIPreS2 (SEQ ID NO: 8) SPPLRDSHPQAMQWNSTAFQQALQDPRVRGLFFPAGGSSSGTVNPAPNIASHISS S-HBsAg (SEQ ID NO: 9)ISSRTGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGONSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFIPLLPIFFCLWVYI M-HBsAg (SEQ ID NO: 10)SPPLRDSHPQAMQWNSTAFQQALQDPRVRGLFFPAGGSSSGTVNPAPNIASHISSISSRTGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFIPL LPIFFCLWVYI L-HBsAg(SEQ ID NO: 11) MGGWSAKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANQVGVGAFGPGFTPPHGGLLGWSSQAQGTLHTVPAVPPPASTNRQTGRQPTPISPPLRDSHPQAMQWNSTAFQQALQDPRVRGLFFPAGGSSSGTVNPAPNIASHISSISSRTGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFIPLLPIFFCLWVYIP03141 Hepatitis B virus genotype A2 subtype adw2 (strain Rutter 1979)

PreS1 (SEQ ID NO: 12) MGGWSSKPRKGMGTNLSVPNPLCFFPDHQLDPAFGANSNNPDWDFNPVKDDWPAANQVGVGAFGPRLTPPHGGILGWSPQAQGILTTVSTIPPP ASTNRQSGRQPTPI PreS2(SEQ ID NO: 13) SPPLRDSHPQAMQWNSTAFHQTLQDPRVRGLYLPAGGSSSGTVNPAP NIASHISSS-HBsAg (SEQ ID NO: 14) ISARTGDPVTNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLLPIF FCLWVYI M-HBsAG(SEQ ID NO: 15) SPPLRDSHPQAMQWNSTAFHQTLQDPRVRGLYLPAGGSSSGTVNPAPNIASHISSISARTGDPVTNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPSLYSIVSPFIPLL PIFFCLWVYI L-HBsAg(SEQ ID NO: 16) MGGWSSKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPVKDDWPAANQVGVGAFGPRLTPPHGGILGWSPQAQGILTTVSTIPPPASTNRQSGRQPTPISPPLRDSHPQAMQWNSTAFHQTLQDPRVRGLYLPAGGSSSGTVNPAPNIASHISSISARTGDPVTNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGSPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWG PSLYSIVSPFIPLLPIFFCLWVYIQ4R1R8 Hepatitis B virus genotype A3 (isolate Cameroon/CMR711/1994)

PreS1 (SEQ ID NO: 17) MGGRLPKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPIKDHWPQANQVGVGAFGPGFTPPHGGVLGWSPQAQGTLTTVPAVPPP ASTNRQSGRQPTPI  PreS2(SEQ ID NO: 18) SPPLRDSHPQAMQWNSTKFHQTLQDPRVRGLYFPAGGSSSGTVNPAP NIASHISSS-HBsAg (SEQ ID NO: 19) ISSRIGDPAPTMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGEAPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDCQGMLPVCPLIPGSTTTSTGPCRTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFIPLLPIFFCLWV YI M-HBsAg(SEQ ID NO: 20) SPPLRDSHPQAMQWNSTKFHQTLQDPRVRGLYFPAGGSSSGTVNPAPNIASHISSISSRIGDPAPTMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGEAPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDCQGMLPVCPLIPGSTTTSTGPCRTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFIPLL PIFFCLWVYI L-HBsAg(SEQ ID NO: 21) MGGRLPKPRKGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPIKDHWPQANQVGVGAFGPGFTPPHGGVLGWSPQAQGTLTTVPAVPPPASTNRQSGRQPTPISPPLRDSHPQAMQWNSTKFHQTLQDPRVRGLYFPAGGSSSGTVNPAPNIASHISSISSRIGDPAPTMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGEAPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDCQGMLPVCPLIPGSTTTSTGPCRTCTTPAQGNSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWG PSLYNILSPFIPLLPIFFCLWVYIQ8JXB9 Hepatitis B virus genotype B1 (isolate Japan/Ry30/2002)

Pres1 (SEQ ID NO: 22) MGGWSSKPRKGMGTNLSVPNPLGFEPDHQLDPAFKANSENPDWDLNPHKDNWPDAHKVGVGAFGPGETPPHGGLLGWSPQAQGILTSVPAAPPP ASTNRQSGRQPTPL PreS2(SEQ ID NO: 23) SPPLRDTHPQAMQWNSTTFHQTLQDPRVRALYLPAGGSSSGTVSPAQ NTVSAISSS-HBsAG (SEQ ID NO: 24) ILSTTGDPVPNMENIASGLLGPLLVLQAGFFSLTKILTIPQSLDSWWTSLSFLGGTPVCLGQNSQSPISSHSPTCCPPICPGYRWMYLRRFIIXLCILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGTSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVOWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFMPLLPIFFCLWV YI M-HBsAg(SEQ ID NO: 25) SPPLRDTHPQAMQWNSTTFHQTLQDPRVRALYLPAGGSSSGTVSPAQNTVSAISSILSTTGDPVPNMENIASGLLGPLLVLQAGFFSLTKILTIPQSLDSWWTSLSFLGGTPVCLGQNSQSPISSHSPTCCPPICPGYRWMYLRRFIIXLCILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGTSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFMPLL PIFFCLWVYI L-HBsAg(SEQ ID NO: 26) MGGWSSKPRKGMGTNLSVPNPLGFFPDHQLDPAFKANSENPDVJDLNPHKDNWPDAHKVGVGAFGPGFTPPHGGLLGwSPQAQGILTSVPAAPPPASTNRQSGRQPTPLSPPLRDTHPQAMQWNSTTFHQTLQDPRVRALYLPAGGSSSGTVSPAQNTVSAISSILSTTGDPVPNMENIASGLLGPLLVLQAGFFSLTKILTIPQSLDSWWTSLSFLGGTPVCLGQNSQSPISSHSPTCCPPICPGYRWMYLRRFIIXLCILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGTSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFMPLLPIFFCLWVYIQ9PWW3 Hepatitis B virus genotype B2 (isolate Vietnam/16091//1992)

PreS1 (SEQ ID NO: 27) MGGWSSKPRKGMGTNLSVPNPLGFFPDHQLDPAFKANSENPDWDLNPHKDNWPDANKVGVGAFGPGFTPPHGGLLGWSPQAQGLLTTVPAAPPP ASTNRQSGRQPTPL PreS2(SEQ ID NO: 28) SPPLRDTHPQAMQWNSTTFHQTLQDPRVRALYFPAGGSSSGTVSPAQ NTVSTISSS-HBsAg (SEQ ID NO: 29) ILSKTGDPVPNMENIASGLLGPLLVLQAGFFLLTKILTIPQSLDSWWTSLNFLGGTPVCLGQNSQSQISSHSPTCCPPICPGYRWMCLRRFIIFLCILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGTSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWFWGPSLYNILSPFMPLLPIFFCLWV YI M-HBsAg(SEQ ID NO: 30) SPPLRDTHPQAMQWNSTTFHQTLQDPRVRALYFPAGGSSSGTVSPAQNTVSTISSILSKTGDPVPNMENIASGLLGPLLVLQAGFFLLTKILTIPQSLDSWWTSLNFLGGTPVCLGQNSQSQISSHSPTCCPPICPGYRWMCLRRFIIFLCILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGTSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWFWGPSLYNILSPFMPLL PIFFCLWVYI L-HBsAg(SEQ ID NO: 31) MGGWSSKPRKGMGTNLSVPNPLGFFPDHQLDPAFKANSENPDWDLNPHKDNWPDANKVGVGAFGPGFTPPHGGLLGWSPQAQGLLTTVPAAPPPASTNRQSGRQPTPLSPPLRDTHPQAMQWNSTTFHQTLQDPRVRALYFPAGGSSSGTVSPAQNTVSTISSILSKTGDPVPNMENIASGLLGPLLVLQAGFFLLTKILTIPQSLDSWWTSLNFLGGTPVCLGQNSQSQISSHSPTCCPPICPGYRWMCLRRFIIFLCILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGTSMFPSCCCTKPTDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWFWG PSLYNILSPFMPLLPIFFCLWVYIQ76R62 Hepatitis B virus genotype C subtype ayr (isolateHuman/Japan/Okamoto/−)

PreS1 (SEQ ID NO: 32) MGGWSSKPRQGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANQVGAGAFGPGFTPPHGGLLGWSPQAQGILTTLPAAPPP ASTNRQSGRQPTPI PreS2(SEQ ID NO: 33) SPPLRDSHPQAMQWNSTTFHQALLDPRVRGLYFPAGGSSSGTVNPVP TTASPISSS-HBsAg (SEQ ID NO: 34) IFSRTGDPAPNMESTTSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGAPTCPGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGTSTTSTGPCRTCTIPAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFARFLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPSLYNILSPFLPLLPIFFCLWV YI M-HBsAg(SEQ ID NO: 35) SPPLRDSHPQAMQWNSTTFHQALLDPRVRGLYFPAGGSSSGTVNPVPTTASPISSIFSRTGDPAPNMESTTSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGAPTCPGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGTSTTSTGPCRTCTIPAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFARFLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPSLYNILSPFLPLL PIFFCLWVYI L-HBsAg(SEQ ID NO: 36) MGGWSSKPRQGMGTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANQVGAGAFGPGFTPPHGGLLGWSPQAQGILTTLPAAPPPASTNRQSGRQPTPISPPLRDSHPQAMQWNSTTFHQALLDPRVRGLYFPAGGSSSGTVNPVPTTASPISSIFSRTGDPAPNMESTTSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGAPTCPGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGTSTTSTGPCRTCTIPAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFARFLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWG PSLYNILSPFLPLLPIFFCLWVYIP03138 Hepatitis B virus genotype D subtype ayw (isolateFrance/Tiollais/1979)

PreS1 (SEQ ID NO: 37) MGQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVGAGAFGLGFTPPHGGLLGWSPQAQGILQTLPANPPPASTNRQSGRQPTP L PreS2 (SEQ ID NO: 38)SPPLRNTHPQAMQWNSTTFHQTLQDPRVRGLYFPAGGSSSGTVNPVLT TASPLSS S-HBsAg(SEQ ID NO: 39) IFSRIGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFCLWVYI M-HBsAg (SEQ ID NO: 40)SPPLRNTHPQAMQWNSTTEHQTLQDPRVRGLYEPAGGSSSGTVNPVLTTASPLSSIFSRIGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFCL WVYI L-HBsAg(SEQ ID NO: 41) MGQNLSTSNPLGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVGAGAFGLGFTPPHGGLLGWSPQAQGILQTLPANPPPASTNRQSGRQPTPLSPPLRNTHPQAMQWNSTTFHQTLQDPRVRGLYFPAGGSSSGTVNPVLTTASPLSSIFSRIGDPALNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNELGGTTVCLGQNSQSPTSNHSPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFC LWVYIQ69603 Hepatitis B virus genotype E subtype ayw4 (isolate Kou) GN=S PE=1SV=2

Pres1 (SEQ ID NO: 42) MGLSWTVPLEWGKNISTTNPLGFFPDHQLDPAFRANTRNPDWDHNPNKDHWTEANKVGVGAFGPGFTPPHGGLLGWSPQAQGMLKTLPADPPPA STNRQSGRQPTPI PreS2(SEQ ID NO: 43) TPPLRDTHPQAMQWNSTTFHQALQDPRVRGLYFPAGGSSSGTVNPVP TTASLISSS-HBsAg (SEQ ID NO: 44) IFSRIGDPAPNMESITSGFLGPLLVLQAGFFLLTKILTIPQSLDSWWTSLNFLGGAPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFAGLSPTVWLSVIWMMWYWGPSLYDILSPFIPLLPIFFCLWV YI M-HBsAg(SEQ ID NO: 45) TPPLRDTHPQAMQWNSTTFHQALQDPRVRGLYFPAGGSSSGTVNPVPTTASLISSIFSRIGDPAPNMESITSGFLGPLLVLQAGFFLLTKILTIPQSLDSWWTSLNFLGGAPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFAGLSPTVWLSVIWMMWYWGPSLYDILSPFIPLL PIFFCLWVYI L-HBsAg(SEQ ID NO: 46) MGLSWTVPLEWGKNISTTNPLGFFPDHQLDPAFBANTRNPDWDHNPNKDHVWTEANKVGVGAFGPGFTPPHGGLLGWSPQAQGMLKTLFADPPPASTNRQSGRQPTPITPPLRDTHPQAMQWNSTTFHQALQDPRVRGLYFPAGGSSSGTVNPVPTTASLISSIFSRIGDPAPNMESITSGFLGPLLVLQAGFFLLTKILTIPQSLDSWWTSLNFLGGAPVCLGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFAGLSPTVWLSVIWMMWYWG PSLYDILSPFIPLLPIFFCLWVYIQ99HS3 Hepatitis B virus genotype F1 (isolate Argentina/sa11/2000)

Pres1 (SEQ ID NO: 47) MGAPLSTTRRGMGQNLSVPNPLGFFPDHQLDPLFRANSSSPDWDFNKNKDNWPMANKVGVGGYGPGPPHGGLLGWSPQAQGVLTTLPADPPPAS TNRRSGRKPTPV PreS2(SEQ ID NO: 48) SPPLRDTHPQAMQWNSTQFHQALLDPRVRALYFPAGGSSSETQNPAP TIASLTSSS-HBsAg (SEQ ID NO: 49) IFLKTGGPATNMDNITSGLLGPLLVLQAVCFLLTKILTIPQSLDSWWTSLNELGGTPGCPGQNSQSPTSNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLVDYQGMLPVCPPLPGSTTTSTGPCKTCTTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWALGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWCPNLCSILSPFIPLLPIFCYLWV SI M-HBsAg(SEQ ID NO: 50) SPPLRDTHPQAMQWNSTQFHQALLDPRVRALYFPAGGSSSETQNPAPTIASLTSSIFLKTGGPATNMDNITSGLLGPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGGTPGCPGQNSQSPTSNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLVDYQGMLPVCPPLPGSTTTSTGPCKTCTTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWALGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWGPNLCSILSPFIPLL PIFCYLWVSI L-HBsAg(SEQ ID NO: 51) MGAPLSTTRRGMGQNLSVPNPLGFFPDHQLDPLFRANSSSPDWDFNKNKDNWPMANKVGVGGYGPGFTPPHGGLLGWSPQAQGVLTTLPADPPPASTNRRSGRKPTPVSPPLRDTHPQAMQWNSTQFHQALLDPRVRALYFPAGGSSSETQNPAPTIASLTSSIFLKTGGPATNMDNITSGLLGPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGGTPGCPGQNSQSPTSNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLVDYQGMLPVCPPLPGSTTTSTGPCKTCTTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWALGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWG PNLCSILSPFIPLLPIFCYLWVSIQ99HR4 Hepatitis B virus genotype F2 (isolate Argentina/sa16/2000)

PreS1 (SEQ ID NO: 52) MGAPLSTTRRGMGQNLSVPNPLGFFPEHQLDPLFRANSSSPDWDFNKNKDTWPMANKVGVGGYGPGFTPPHGGLLGWSPQAQGVLTTLPADPPP ASTNRRSGRKPTPV PreS2(SEQ ID NO: 53) SPPLRDTHPQAMQWNSTQFHQALLDPRVRALYFPAGGSSSETQNPAP TIASLTSSS-HBsAg (SEQ ID NO: 54) IFSKTGGPAMNMDSITSGLLGPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGGLPGCPGQNSQSPTSNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWALGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWGPNLCSILSPFIPLLPIFCYLWV SI M-HBsAg(SEQ ID NO: 55) SPPLRDTHPQAMQWNSTQFHQALLDPRVRALYFPAGGSSSETQNPAPTIASLTSSIFSKTGGPAMNMDSITSGLLGPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGGLPGCPGQNSQSPTSNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWALGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWGPNLCSILSPFIPLL PIFCYLWVSI L-HBsAg(SEQ ID NO: 56) MGAPLSTTRRGMGQNLSVPNPLGFFPEHQLDPLFRANSSSPDWDFNKNKDTWPMANKVGVGGYGPGFTPPHGGLLGWSPQAQGVLTTLPADPPPASTNRRSGRKPTPVSPPLRDTHPQAMQWNSTQFHQALLDPRVRALYFPAGGSSSETQNPAPTIASLTSSIFSKTGGPAMNMDSITSGLLGPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGGLPGCPGQNSQSPTSNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSTTTSTGPCKTCTTLAQGTSMFPSCCCSKPSDGNCTCIPIPSSWALGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWG PNLCSILSPFIPLLPIFCYLWVSIQ9IBI3 Hepatitis B virus genotype G (isolate IG29227/2000)

PreS1 (SEQ ID NO: 57) MGLSWTVPLEWGKNLSASNPLGFLPDHQLDPAFRANTNNPDWDENPKKDPWPEANKVGVGAYGPGETPPHGGLLGWSPQSQGTLTTLPADPPPA STNRQSGRQPTPI PreS2(SEQ ID NO: 58) SPPLRDSHPQAMQWNSTAFHQALQNPKVRGLYFPAGGSSSGIVNPVP TIASHISSS-HBsAg (SEQ ID NO: 59) IFSRIGDPAPNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGVPVCPGLNSQSPTSNHSPISCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGNSMYPSCCCTKPSDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPNLYNILSPFIPLLPIFFCLWV YI M-HBsAg(SEQ ID NO: 60) SPPLRDSHPQAMQWNSTAFHQALQNPKVRGLYFPAGGSSSGIVNPVPTIASHISSIFSRIGDPAPNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGVFVCPGLNSQSPTSNHSPISCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGNSMYPSCCCTKPSDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGPNLYNILSPFIPLL PIFFCLWVYI L-HBsAg(SEQ ID NO: 61) MGLSWTVPLEWGKNLSASNPLGFLPDHQLDPAFRANTNNPDWDENPKKDPWPEANKVGVGAYGPGFTPPHGGLLGWSPQSQGTLTTLPADPPPASTNRQSGRQPTPISPPLRDSHPQAMQWNSTAFHQALQNPKVRGLYFPAGGSSSGIVNPVPTIASHISSIFSRIGDPAPNMENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGVPVCPGLNSQSPTSNHSPISCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCKTCTTPAQGNSMYPSCCCTKPSDGNCTCIPIPSSWAFAKYLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSAIWMMWYWGP NLYNILSPFIPLLPIFFCLWVYIQ8JMY6 Hepatitis B virus genotype H (isolate United States/LAS2523/2002)

PreS1 (SEQ ID NO: 62) MGAPLSTARRGMGQNLSVPNPLGFFPDHQLDPLFRANSSSPDWDFNTNKDNWPMANKVGVGGFGPGFTPPHGGLLGWSPQAQGILTTSPPDPPP ASTNRRSGRKPTPV PreS2(SEQ ID NO: 63) SPPLRDTHPQAMQWNSTQFHQALLDPRVRGLYFPAGGSSSETQNPAP TIASLTSSS-HBsAg (SEQ ID NO: 64) IFSKTGDPAMNMENITSGLLRPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGVPPGCPGQNSQSPISNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGSTTTSTGPCKTCTTLAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWGPNLCSILSPFIPLLPIFCYLWA SI M-HBsAg(SEQ ID NO: 65) SPPLRDTHPQAMQWNSTQFHQALLDPRVRGLYFPAGGSSSETQNPAPTIASLTSSIFSKTGDPAMNMENITSGLLRPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGVPPGCPGQNSQSPISNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGSTTTSTGPCKTCTTLAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWGPNLCSILSPFIPLL PIFCYLWASI  L-HBsAg(SEQ ID NO: 66) MGAPLSTARRGMGQNLSVPNPLGFFPDHQLDPLFRANSSSPDWDFNTNKDNWPMANKVGVGGFGPGFTPPHGGLLGWSPQAQGILTTSPPDPPPASTNRRSGRKPTPVSPPLRDTHPQAMQWNSTQFHQALLDPRVRGLYFPAGGSSSETQNPAPTIASLTSSIFSKTGDPAMNMENITSGLLRPLLVLQAVCFLLTKILTIPQSLDSWWTSLNFLGVPPGCPGQNSQSPISNHLPTSCPPTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGSTTTSTGPCKTCTTLAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFGKYLWEWASARFSWLSLLVQFVQWCVGLSPTVWLLVIWMIWYWG PNLCSILSPFIPLLPIFCYLWASI

In various further embodiments, the composition may comprise anHBVpreS1/S2Ag or S-HBsAg polypeptide at least 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99%, or 100% identical over the length of the amino acidsequence of the sequences shown above. In various embodiments,additional HBVpreS1/S2Ag mutations may be included (alone or incombination). These mutations may include, but are not limited to, thepreS1 S98T substitution (PLOS One 9: e110012, 2014), the preS1 F53Lsubstitution (J Med Virol 85: 1698, 2013), or the preS1 A39R and preS1S96A/T substitutions (Clin Microbial Infect 18: E412, 2012).

In all of these embodiments, the composition may further comprise anamino acid linker position between the CD180 binding ligand and theHBVpreS1/S2Ag or S-HBsAg. The linker may be of any suitable length andamino acid composition, depending on the intended use. In oneembodiment, the linker is between about 2-40 amino acids in length. Inother embodiments, the linker may be between 10-30 or 15-25 amino acidsin length. In another embodiment, the linker may be a linker rich inglycine and serine residues. In one specific embodiment, the linker maycomprise the amino acid sequence

GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 69).

In various further embodiments, the composition may comprise or consistof a polypeptide at least 90% identical over its length to the followingamino acid sequence of G28-8LH-scAb-PreS1-S2-His protein (expressed)

(SEQ ID NO: 67)   (METPAQLLFL LLLWLPDTTG) DIQMTQSPAS  LSASVGETVT ITCRASEKIY SYLAWYQQKQ  61 GKSPQLLVYN AKTLAEGVPS RFSVSGSGTQ    FSLRINSLQP EDFGTYYCQH HFGSPRTFGG 121 GTKLEIKDLG GGGSGGGGSG GGGSGGGGST      GEVQLQQSGP   ELVKPGASMK ISCKASGYSF181 TGYTMNWVKQ SHGKTLEWIG LINPYNGVTS      YNQKFKDKAT  LTVDKSSSTA YMELLSLTSE 241 DSAIYYCARD YNYDYFDYWG QGTTLTVSS D    LEPKSSDKTH TCPPCPAPEL LGGSSVFLFP301 PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK    FNWYVDGVEV HNAKTKPREE QYNSTYRVVS361 VLTVLHQDWL NGKEYKCSVS NKALPASIEK    TISKAKGQPR EPQVYTLPPS REEMTKNQVS421 LTCLVKGFYP SDIAVEWESN GQPENNYKTT    PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS481 CSVMHEALHN HYTQKSLSLS PGKGGGGSGG    GGSGGGGSGG GGSMGGWSSK PRQGMGTNLS541 VPNPLGFFPD HQLDPAFGAN SNNPDWDFNP    VNKDHWPEANQ GAGAFGPGF TPPHGGLLGW601 SPQAQGILTT LPAAPPPAST NRQSGRQPTP    ISPPLRDSHP QAMQWNSTTF HQALLDPRVR661 GLYFPAGGSS SGTVNPVPTT ASPISSIFSR     TGDPAPN (HHH HHH) Amino acids1-20: Leader (optional) Amino acids 21-129: G2 8-8VL (Bold) Amino acids130-149 : Gly-Ser Linker Amino acids 150-269 : G28-8VH (Bold andunderlined) Amino acids 270-503 : Hing-CH2-CH3 Amino acids 504-533:Gly-Ser Linker Amino acids 534-597: preS1/preS2 Amino acids 698-703:6xHis Residues in parentheses are optional

The compositions of any embodiment or combination of embodiments of thedisclosure may be provided as a stand-alone composition, or may beprovided as part of a molecular scaffold. In various embodiments, thecomposition may be attached to molecular scaffold. Any suitable scaffoldcan be used, including but not limited to a VNAR single domain antibody(shark variable new antigen receptor), a lamprey variable lymphocytereceptor, a Im 7(colicin immunity 7 protein), an anticalin (lipocalintransport proteins), an FN3 (fibronectin 3) monobody, a DARPin (designedankyrin repeat proteins), an affibody (Z domain of protein A), a singledomain antibody, e.g, isolated from camelids or antibody libraries, andaptamer, etc., with CD180-binding polypeptide loops.

In another embodiment, the composition of any embodiment or combinationof embodiments of the disclosure further comprises an adjuvant. Whileadjuvant is not required to induce rapid activation of HBVpreS1/S2Ag orS-HBsAg, addition of adjuvant to the compositions can result inadditional enhancement of the immune response when the compositions areused in the methods of the disclosure. Any suitable adjuvant can beused, including but not limited to inorganic compounds (aluminumhydroxide, aluminum phosphate, calcium phosphate hydroxide, beryllium,etc.), mineral oil, detergents, cytokines, toll-like receptor agonists,Freund's complete adjuvant, Freund's incomplete adjuvant, squalene, etc.In a preferred embodiment, the adjuvant comprises or consists of atoll-like receptor 4 (TLR4) agonist, a toll-like receptor 7 (TLR7)agonist, a toll-like receptor 8 (TLR8) agonist, a toll-like receptor 9(TLR9) agonist, alum-containing adjuvant, monophosphoryl lipid A,oil-in-water emulsion, and a-tocopherol, squalene and polysorbate 80 inan oil-in-water emulsion. The adjuvant may be present in the compositionas an unlinked component or a linked component, depending on theadjuvant used.

In another embodiment, the compositions of the disclosure can bemodified to extend half-life, such as by attaching at least one moleculeto the composition for extending serum half-life, including but notlimited to a polyethlyene glycol (PEG) group, serum albumin, a serumalbumin binding domain, transferrin, transferrin receptor or thetransferrin-binding portion thereof, or combinations thereof. As usedherein, the word “attached” refers to a covalently or noncovalentlyconjugated substance. The conjugation may be by genetic engineering orby chemical means.

The compositions of the present disclosure may be stored in any suitablebuffer.

In a second aspect, the present disclosure provides isolated nucleicacids encoding the composition of any embodiment of the first aspect ofthe disclosure. The isolated nucleic acid sequence may comprise RNA orDNA. Such isolated nucleic acid sequences may comprise additionalsequences useful for promoting expression and/or purification of theencoded protein, including but not limited to polyA sequences, modifiedKozak sequences, and sequences encoding epitope tags, export signals,and secretory signals, nuclear localization signals, and plasma membranelocalization signals. In one non-limiting embodiment, the isolatednucleic acids encode a polypeptide of the disclosure noted herein. Inother embodiments, the isolated nucleic acids comprise or consist of thenucleotide sequence shown below.

G28-8LH-scAb-PreS1-S2-His 2142 bp (SEQ ID NO: 68)   1 GCGAAGCTTT GAGCCACCAT GGAAACCCCA GCGCAGCTTC TCTTCCTCCT GCTACTCTGG  61 CTCCCAGATA CCACCGGTGA CATCCAGATG ACTCAGTCTC CAGCCTCCCT ATCTGCATCT 121 GTGGGAGAAA CTGTCACCAT CACATGTCGA GCAAGTGAGA AGATTTACAG TTATTTAGCA 181 TGGTATCAGC AGAAACAGGG AAAATCTCCT CAGCTCCTGG TCTATAACGC AAAAACCTTA 241 GCAGAAGGTG TGCCATCAAG GTTCAGTGTC AGTGGATCAG GCACACAGTT TTCTCTGAGG 301 ATCAACAGCC TGCAGCCTGA AGATTTTGGG ACTTATTACT GTCAACATCA TTTTGGTTCT 561 CCTCGGACGT TCGGTGGAGG CACCAAACTG GAAATCAAAG ATCTCGGAGG AGGTGGCTCA 421 GGTGGTGGAG GATCTGGAGG AGGTGGGAGT GGTGGAGGTG GTTCTACCGG TGAGGTCCAG 481 CTGCAACAGT CTGGACCTGA ACTGGTGAAG CCTGGAGCTT CAATGAAGAT ATCCTGCAAG 541 GCTTCTGGTT ACTCATTCAC TGGCTACACC ATGAACTGGG TGAAGCAGAG CCATGGAAAG 601 ACCCTTGAAT GGATTGGACT TATTAATCCT TACAATGGTG TTACTAGCTA CAACCAGAAG 661 TTCAAGGACA AGGCCACATT AACTGTAGAC AAGTCATCCA GCACAGCCTA CATGGAACTC 721 CTCAGTCTGA CATCTGAGGA CTCTGCAATC TATTACTGTG CAAGAGACTA TAATTACGAC 781 TACTTTGACT ACTGGGGCCA AGGCACCACT CTCACAGTCT CCTCAGATCT CGAGCCCAAA 841 TCTTCTGACA AAACTCACAC ATGTCCACCG TGTCCAGCAC CTGAACTCCT GGGTGGATCG 901 TCAGTCTTCC TCTTCCCCCC AAAACCCAAG GACACTCTCA TGATCTCCCG GACCCCTGAG 961 GTCACGTGCG TGGTGGTGGA CGTGAGCCAC GAAGACLCCG AGGTCAAGTT CAACTGGTAC1021 GTGGACGGCG TGGAGGTGCA TAATGCCAAG ACAAAGCCAC GGGAGGAGCA GTACAACAGC1081 ACGTACCGTG TGGTCAGCGT CCTCACCGTC TTGCACCAGG ACTGGCTGAA CGGCAAGGAG1141 TACAAGTGCT CGGTCTCCAA CAAAGCCCTC CCAGCCTCCA TCGAGAAAAC AATCTCCAAA1201 GCCAAAGGGC AGCCCCGAGA ACCACAGGTG TACACCCTGC CCCCATCCCG GGAGGAGATG1261 ACCAAGAACC AGGTCAGCCT GACCTGCCTG GTCAAAGGCT TCTATCCCAG CGACATCGCC1321 GTGGAGTGGG AGAGCAATGG GCAGCCGGAG AACAACTACA AGACCACGCC TCCCGTGCTG1381 GACTCCGACG GCTCCTTCTT CCTCTACAGC AAGCTCACCG TGGACAAGAG CAGGTGGCAG1441 CAGGGGAACG TCTTCTCATG CTCCGTGATG CATGAGGCTC TGCACAACCA CTACACGCAG1501 AAJAGCCTCT CTCTGTCTCC GGGTAAAGGA GGAGGTGGCT CAGGTGGTGG AGGATCTGGA1561 GGAGGTGGGA GTGGTGGAGG TGGTTCTATG GGAGGTTGGT CTTCCAAACC TCGACAAGGC1621 ATGGGGACGA ATCTTTCTGT TCCCAATCCT CTGGGATTCT TTCCCGATCA CCAGTTGGAC1681 CCTGCGTTCG GAGCCAACTC AAACAATCCA GATTGGGACT TCAACCCCAA CAAGGATCAC1741 TGGCCAGAGG CAAATCAGGT AGGAGCGGGA GCATTTGGTC CAGGGTTCAC CCCACCACAC1801 GGAGGCCTTT TGGGGTGGAG CCCTCAGGCT CAGGGCATAT TGACAACACT GCCAGCAGCA1861 CCTCCTCCTG CCTCCACCAA TCGGCAGTCA GGAAGACAGC CTACTCCCAT CTCTCCACCT1921 CTAAGAGACA GTCATCCTCA GGCCATGCAG TGGAACTCCA CAACATTCCA CCAAGCTCTG1981 CTAGATCCCA GAGTGAGGGG CCTATATTTT CCTGCTGGTG GCTCCAGTTC CGGAACAGTA2041 AACCCTGTTC CGACTACTGC CTCACCCATA TCGTCAATCT TCTCGAGGAC TGGGGACCCT2101 GCACCGAACC ACCACCATCA TCATCATTGA TAAGGATCCG CG

-   -   5′ end HindIII and 3′ end BamHl sites for directional cloning        into appropriate expression vector    -   Kozak consensus, GCCACC, right before 5′ ATG start codon    -   One 5′ in frame stop codon after 5′ end HindIII site    -   Two in frame stop codons before 3′ end BamHI site

In a third aspect, the present disclosure provides nucleic acid vectorscomprising the isolated nucleic acid of the second aspect of thedisclosure. “Recombinant expression vector” includes vectors thatoperatively link a nucleic acid coding region or gene to any promotercapable of effecting expression of the gene product. The promotersequence used to drive expression of the disclosed nucleic acidsequences in a mammalian system may be constitutive (driven by any of avariety of promoters, including but not limited to, CMV, SV40, RSV,actin, EF) or inducible (driven by any of a number of induciblepromoters including, but not limited to, tetracycline, ecdysone,steroid-responsive). The expression vector must be replicable in thehost organisms either as an episome or by integration into hostchromosomal DNA. In a preferred embodiment, the expression vectorcomprises a plasmid. However, the disclosure is intended to includeother expression vectors that serve equivalent functions, such as viralvectors.

The nucleic acids and vectors of the disclosure can be used not only forproduction of large quantities of the compositions of the disclosure,but also for use as a nucleic acid (such as a DNA) vaccine administeredby gene gun or other methods.

In a fourth aspect, the present disclosure provides recombinant hostcells comprising the nucleic acid vector of the third aspect of thedisclosure. The host cells can be either prokaryotic or eukaryotic. Thecells can be transiently or stably transfected. Such transfection ofexpression vectors into prokaryotic and eukaryotic cells (including butnot limited to Chinese hamster ovary (CHO) cells) can be accomplishedvia any suitable means, including but not limited to bacterialtransformations, calcium phosphate co-precipitation, electroporation, orliposome mediated-, DEAE dextran mediated-, polycationic mediated-, orviral mediated transfection.

The recombinant host cells can be used, for example in methods forproducing antibody (when the binding protein is an antibody),comprising:

(a) culturing the recombinant host cell of the disclosure underconditions suitable for expression of the nucleic-acid encoded antibodycomposition; and

(b) isolating the antibody composition from the cultured cells.

Suitable conditions for expression of the nucleic-acid encoded antibodycomposition can be determined by those of skill in the art based on theteachings herein and the specific host cells and vectors used.

The term “recombinant” when used with reference, e.g., to a cell, ornucleic acid, protein, or vector, indicates that the cell, nucleic acid,protein or vector, has been modified by the introduction of aheterologous nucleic acid or protein or the alteration of a nativenucleic acid or protein, or that the cell is derived from a cell somodified. Thus, e.g., recombinant cells express genes that are not foundwithin the native (non-recombinant) form of the cell or express nativegenes that are otherwise abnormally expressed, under expressed or notexpressed at all. By the term “recombinant nucleic acid” herein is meantnucleic acid, originally formed in vitro, in general, by themanipulation of nucleic acid, e.g., using polymerases and endonucleases,in a form not normally found in nature. In this manner, operable linkageof different sequences is achieved. Thus an isolated nucleic acid, in alinear form, or an expression vector formed in vitro by ligating DNAmolecules that are not normally joined, are both considered recombinantfor the purposes disclosed herein. It is understood that once arecombinant nucleic acid is made and reintroduced into a host cell ororganism, it will replicate non-recombinantly, i.e., using the in vivocellular machinery of the host cell rather than in vitro manipulations;however, such nucleic acids, once produced recombinantly, althoughsubsequently replicated non-recombinantly, are still consideredrecombinant for the purposes disclosed herein.

In a fifth aspect, the present disclosure provides pharmaceuticalcompositions, comprising:

(a) the composition, isolated nucleic acid, or recombinant expressionvector of any embodiment or combination of embodiments disclosed herein;and

(b) a pharmaceutically acceptable carrier.

In this embodiment, the compositions of the disclosure are present in apharmaceutical formulation. In this embodiment, the compositions arecombined with a pharmaceutically acceptable carrier. Suitable acidswhich are capable of forming such salts include inorganic acids such ashydrochloric acid, hydrobromic acid, perchloric acid, nitric acid,thiocyanic acid, sulfuric acid, phosphoric acid and the like; andorganic acids such as formic acid, acetic acid, propionic acid, glycolicacid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinicacid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid,naphthalene sulfonic acid, sulfanilic acid and the like. Suitable basescapable of forming such salts include inorganic bases such as sodiumhydroxide, ammonium hydroxide, potassium hydroxide and the like; andorganic bases such as mono-, di- and tri-alkyl and aryl amines (e.g.,triethylamine, diisopropyl amine, methyl amine, dimethyl amine and thelike) and optionally substituted ethanol-amines (e.g., ethanolamine,diethanolamine and the like).

The pharmaceutical composition may comprise in addition to thecomposition of the disclosure (a) a lyoprotectant; (b) a surfactant; (c)a bulking agent; (d) a tonicity adjusting agent; (e) a stabilizer; (f) apreservative and/or (g) a buffer. In some embodiments, the buffer in thepharmaceutical composition is a Tris buffer, a histidine buffer, aphosphate buffer, a citrate buffer or an acetate buffer. Thepharmaceutical composition may also include a lyoprotectant, e.g.sucrose, sorbitol or trehalose. In certain embodiments, thepharmaceutical composition includes a preservative e.g. benzalkoniumchloride, benzethonium, chlorohexidine, phenol, m-cresol, benzylalcohol, methylparaben, propylparaben, chlorobutanol, o-cresol,p-cresol, chlorocresol, phenylmercuric nitrate, thimerosal, leenzoicacid, and various mixtures thereof. In other embodiments, thepharmaceutical composition includes a bulking agent, like glycine. Inyet other embodiments, the pharmaceutical composition includes asurfactant e.g., polysorbate-20, polysorbate-40, polysorbate-60,polysorbate-65, polysorbate-80 polysorbate-85, poloxamer-188, sorbitanmonolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitanmonooleate, sorbitan trilaurate, sorbitan tristearate, sorbitantrioleaste, or a combination thereof. The pharmaceutical composition mayalso include a tonicity adjusting agent, e.g., a compound that rendersthe formulation substantially isotonic or isoosmotic with human blood.Exemplary tonicity adjusting agents include sucrose, sorbitol, glycine,methionine, mannitol, dextrose, inositol, sodium chloride, arginine andarginine hydrochloride. In other embodiments, the pharmaceuticalcomposition additionally includes a stabilizer, e.g., a molecule which,when combined with a protein of interest substantially prevents orreduces chemical and/or physical instability of the protein of interestin lyophilized or liquid form. Exemplary stabilizers include sucrose,sorbitol, glycine, inositol, sodium chloride, methionine, arginine, andarginine hydrochloride.

The pharmaceutical compositions of the disclosure may be made up in anysuitable formulation, preferably in formulations suitable foradministration by injection. Such pharmaceutical compositions can beused, for example, in methods of use as vaccines, prophylactics, ortherapeutics.

The pharmaceutical compositions may contain any other components asdeemed appropriate for a given use, such as additional therapeutics orvaccine components. In one embodiment, the pharmaceutical compositionsfurther comprise toll-like receptor 4 (TLR4) agonist, a toll-likereceptor 7 (TLR7) agonist, a toll-like receptor 8 (TLR8) agonist, atoll-like receptor 9 (TLR9) agonist, alum-containing adjuvant,monophosphoryl lipid A, oil-in-water emulsion, and α-tocopherol,squalene and polysorbate 80 in an oil-in-water emulsion.

In a sixth aspect, the present disclosure provides methods for treatingor limiting development of an HBV infection or a hepatitis-B virus(HBV)-related disorder, comprising administering to an individual inneed thereof an amount effective to treat or limit development of thedisorder of the composition, isolated nucleic acid, recombinantexpression vector, or pharmaceutical composition, or a pharmaceuticalsalt thereof, of any embodiment or combination of embodiments of thepresent disclosure. In one embodiment, the compositions are usedprophylactically as vaccines to limit development of HBV infectiondisease/severity of infectious disease, such as in individuals that havenot been exposed to an infectious agent but are at risk of suchexposure. In other embodiments, the methods can be used therapeuticallyto treat people exposed to or chronically infected with HBV.

The methods of the disclosure target antigen to CD180, a surface proteinexpressed on B cells, macrophages, and dendritic cells, that to produceantigen-specific IgG in the absence of T cell costimulation (such asCD40 deficiency) or the complete absence of T cells (such as TCR β/δdeficiency). Thus, the methods can be used in any therapeutic orprophylactic treatment for HBV infection or vaccination. This approachalso finds use, for example, for neonates, the elderly, theimmunocompromised, and the immunodeficient, both in specificallytargeting cellular populations enriched in underdeveloped or otherwisedeficient immune systems and by improving responses to antigens thatrequire linked recognition (carbohydrate epitopes, etc.).

As used herein, “treat” or “treating” means accomplishing one or more ofthe following in an individual that already has a disorder or hasalready been exposed to a disorder-causing substance/pathogen: (a)reducing the severity of the disorder; (b) limiting or preventingdevelopment of symptoms characteristic of the disorder(s) being treated(ex:

immune deficiencies in cancer patients or other patients) undergoingchemotherapy and/or radiation therapy); (c) inhibiting worsening ofsymptoms characteristic of the disorder(s) being treated; (d) limitingor preventing recurrence of the disorder(s) in patients that havepreviously had the disorder(s); and (e) limiting or preventingrecurrence of symptoms in patients that were previously symptomatic forthe disorder(s).

As used herein, “limiting” or “limiting development of” meansaccomplishing one or more of the following in an individual that doesnot have the disorder to be limited: (a) preventing the disorder; (b)reducing the severity of the disorder; and (c) limiting or preventingdevelopment of symptoms characteristic of the disorder.

As used herein, an “amount effective” refers to an amount of thecomposition that is effective for treating and/or limiting the relevantdisorder.

While the methods of the disclosure do not require use of an adjuvant,the methods may further comprise administering an adjuvant for possibleadditional enhancement of the immune response Any suitable adjuvant canbe used, including but not limited to toll-like receptor 4 (TLR4)agonist, a toll-like receptor 7 (TLR7) agonist, a toll-like receptor 8(TLR8) agonist, a toll-like receptor 9 (TLR9) agonist, alum-containingadjuvant, monophosphoryl lipid A, oil-in-water emulsion, anda-tocopherol, squalene and polysorbate 80 in an oil-in-water emulsion.

The individual may be any suitable individual, including but not limitedto mammals. Preferably the individual is a human. In one embodiment, theindividual has a T-cell deficiency and/or a defect in co-stimulationbetween B cells and T cells, or is immuno-compromised by chronicinfections or from acute or chronic taking of immunosuppressive drugsfor treatment of autoimmune diseases, or other inflammatory disease . Inanother embodiment, the individual is less than one month old or iselderly (i.e.: at least 65 years old).

In various other embodiments, the individual has a hepatitis B-relateddisease, such as hepatitis, hepatitis-related disease, fulminanthepatitis, cirrhosis, and/or hepatocellular carcinoma, and the methodsare used to treat the a hepatitis B-related disease, such as hepatitis,hepatitis-related disease, fulminant hepatitis, cirrhosis, and/orhepatocellular carcinoma.

EXAMPLE 1

Generation and characterization of G28-8LH-scAb-PreS1-S2-His recombinantprotein molecules.

G28-8LH-scAb-PreS1-S2-His_protein_(expressed) (SEQ ID NO: 67)  1 (METPAQLLFL LLLWLPDTTG) DIQMTQSPAS     LSASVGETVT ITCRASEKIY SYLAWYQQKQ 61 GKSPQLLVYN AKTLAEGVPS RFSVSGSGTQ     FSLRINSLQP EDFGTYYCQH HFGSPRTFGG 121 GTKLEIKDLG GGGSGGGGSG GGGSGGGGST      GEVQLQQSGP   ELVKPGASMK ISCKASGYSF 181 TGYTMNWVKQ SHGKTLEWIG LINPYNGVTS      YNQKFKDKAT   LTVDKSSSTA YMELLSLTSE241 DSAIYYCARD Y NYDYFDYWG QGTTLTVSS D    LEPKSSDKTH TCPPCPAPEL LGGSSVFLFP301 PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK    FNWYVDGVEV HNAKTKPREE QYNSTYRVVS361 VLTVLHQDWL NGKEYKCSVS NKALPASIEK    TISKAKGQPR EPQVYTLPPS REEMTKNQVS421 LTCLVKGFYP SDIAVEWESN GQPENNYKTT    PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS481 CSVMHEALHN HYTQKSLSLS PGKGGGGSGG    GGSGGGGSGG GGSMGGWSSK PRQGMGTNLS541 VPNPLGFFPD HQLDPAFGAN SNNPDWDFNP    NKDHWPEANQ VGAGAFGPGE TPPHGGLLGW601 SPQAQGILTT LPAAPPPAST NRQSGRQPTP    ISPPLRDSHP QAMQWNSTTE HQALLDPRVR661 GLYFPAGGSS SGTVNPVPTT ASPISSIFSR     TGDPAPN(HHH HHH) Amino acids1-20: Leader (optional) Amino acids 21-129: G28-8VL (Bold) Amino acids130-149: Gly-Ser Linker Amino acids 150-269: G28-8VH (Bold andunderlined) Amino acids 270-503: Hing-CH2-CH3 Amino acids 504-533:Gly-Ser Linker Amino acids 534-697: preS1/preS2 Amino acids 698-703:6xHis Residues in parentheses are optional

G28-8 (anti-human CD180)-scAb-PreS1/S2 recombinant protein molecules.The inventors have demonstrated that for the specific anti-CD180antibody, G28-8, a single chain antibody (scAb) in the form ofVLVH-human IgG1 Fc retains both the efficient binding as well as thebiological properties of its parent G28-8 IgG. The G28-8LH scAb is usedto create G28-8LH-scAb-PreS1-S2-His recombinant protein constructs. Itis anticipated that scFv generated from other anti-CD180 antibodies mayretain the antibody characteristics in either the VLVH, VHVL, or onlythe VHVL configuration.

Production of recombinant the G28-8LH-scAb-PreS1-S2-His protein.Complementary DNAs (cDNAs) encoding the G28-8LH-scAb-PreS1-S2-Hisrecombinant proteins (FIG. 1 , G28-8LH-scAb-PreS1-S2-His protein) werecloned into the mammalian expression vector pTT5 that harbors a CMVpromoter to drive protein expression. Transient transfection of theseplasmids into Chinese hamster ovary (CHO) cells was done usingLipofectamine™ reagents (Invitrogen Carlsbad, Calif.) orpolyethyleninmine (PEI). Small-scale transfection optimization using 5%,20% and 80% ratios of expression plasmid in the lipofection reagent wasconducted to identify to optimal plasmid to lipofection reagent ratiosfor larger scale expression. Once optimized transfection conditions areestablished, a large-scale transfection will be conducted for each ofthe plasmids for recombinant protein production. Nickel affinitychromatography, e.g., using the HisPurNi-NTA^(Tm) resin (Thermo FisherScientific Inc., Rockford Ill.), was used to purify the recombinantproteins. The cDNA sequences for the G28-8LH-scAb-HBV-PreS1/S2 proteinpredicts a polypeptide size of ˜75 kDa. The expressed dimeric form ofthe recombinant protein is predicted to have a molecular weight of 150kDa.

FIG. 2 shows the results from a 2-liter expression run. The plasmidencoding the G28-8LH-scAb-PreS1-S2-His protein was transiently expressedin CHO cells for 8 days. Culture supernatants (˜2 liters) were collectedand cellular debris was removed by centrifugation. Clarified culturesupernatants were then loaded on to a column containing HisPurNi-NTA™resin. After washing the column with the wash buffer (50 mM phosphatebuffer, pH 7.0, 300 mM NaCl, 1 mM imidazole), bound recombinant proteinwas eluted with the elution buffer (50 mM phosphate buffer, pH 7.0, 300mM NaCl, 150 mM imidazole). Protein containing fractions as monitored byabsorbance at 280 nM were collected, pooled, and dialyzed againstphosphate-buffer saline at pH 7.0. Purified G28-8LH-scAb-PreS1-S2-Hisand unbound flow through materials from HisPurNi-NTA™ chromatography wasanalyzed on SDS-PAGE (4-15% gradient under reducing conditions) stainedwith Coomassie blue. FIG. 2 , left panel shows a major protein bandmigrating at the MW of ˜85 kDa, suggesting thatG28-8LH-scAb-PreS1-S2-His protein was in fact expressed by CHO cells asan intact protein and secreted into the culture supernatants. Aduplicate gel was then transferred onto a nylon membrane andimmuno-blotted with an anti-6×-His antibody. Intense anti-6× His signalswere only observed at ˜85 kDa (FIG. 2 , right panel), at the identicalMW G28-8LH-scAb-PreS1-S2-His migrated to on the Coomassie blue stainedgel (FIG. 2 , left panel).

EXAMPLE 2 Characterization of G28-8LH-scAb-PreS1-S2-His

FIG. 3 shows that human CD20+ tonsillar B cells (10⁶) were incubated in96 well round bottom plates with PBSA (PBS w/0.2% BSA+0.2% NaN3) mediaonly (gray) or with the His tagged recombinant protein containing thelight and heavy chains of G28-8 anti-human CD180 (LH)G28-8LH-scAb-PreS1-S2-His (black), at 10 μg/ml. After a 40 minincubation on ice, the cells were washed twice (centrifuged at 1200 rpm,4 min). Then 100 μl of PBSA+5 μl a fluorescein (FITC)-conjugated anti 6×His (FITC-6×-His epitope tag ThermoScientific MA1-81891) were added tothe wells, and after a 40 min incubation on ice, cells were washed twiceand the level of fluorescence measured by flow cytometry shown onabscissa (log scale). Unstained cells are shown in black. Therecombinant protein bound to B cells as shown by binding being above theFITC control, demonstrating binding to CD180 expressed on B cells.

Ligation of CD180 on B cells has been shown to upregulate CD40expression⁵¹. The ability of G28-8LH-scAb-PreS1-S2-His to upregulateCD40 expression was then tested to evaluate its functional activity(FIG. 4 ). Er-blood mononuclear cells enriched for B cells wereincubated for 24 hrs at 37C with either media (gray line) or 10 μg/ml ofG28-8LH-scAb-HBV-PreS1/S2-His (black line). Samples were washed twicewith PBSA, stained with mAb specific for CD20 (Pacific Blue Biolegend™)and CD40 (FITC BD BioSciences) and evaluated for CD40 and CD20expression using flow cytometry. Graph shows CD40 expression of gatedCD20⁺ B cells. G28-8LH-scAb-PreS1-S2-His upregulated CD40 expression,confirming that G28-8LH-scAb-PreS1-S2-His was functionally active (FIG.4 ).

EXAMPLE 3

Induction in Macaques of preS1-S2-Specific IgG Antibody Responses byG28-8LH-scAb-PreS1-S2-His Recombinant Protein

The ability of G28-8LH-scAb-PreS1-S2-His to induce humoral and cellularimmune responses was examined in a vaccination experiment in cynomolgusmacaques (Macaca fascicularis). Groups of macaques (N=3) were vaccinatedsubcutaneously with either: 1) 300 pg of G28-8LH-scAb-PreS1-S2-His(aCD180-HBV-PreS1/S2) in 1 ml; or 2) 300 μg of G28-8LH-scAb-PreS1-S2-Hisco-formulated with 100 μg of the commercial adjuvant AddaVax™(InVivoGen, San Diego, Calif.) in a total of 1 ml. Animals werevaccinated on days 0 and 30 and serum and heparinized blood samples wereobtained on days 0, 7, 14, 30 (time-points after first dose), 37, 44 and60 (time-points after second dose). Serum samples were assessed for IgGantibody responses to HBV preS1 by ELISA as follows: a) coating 96 wellplates with 200 ng/well purified recombinant preS1 peptide (115 aminoacids, Cosmo Bio. Japan cat# BCL-AGS1-01); b) adding serial dilutions ofserum samples (100 pl diluted in TBS+0.05% tween-20) starting with a1:1000 dilution, followed by washing and adding HRP-anti-macaque IgGsecond step (Rockland, 1:5000 dilution). Both groups produced IgG afterimmunizations (FIG. 5A). The antibody titers increased after each boost.The group receiving recombinant protein with AddaVax™ adjuvant hadhigher IgG antibody responses compared to group not given AddaVax™ attwo time points after the second immunization.

EXAMPLE 4

Induction in macaques of HBV-specific T cell responses byG28-8LH-scAb-PreS1-S2-His

To determine the frequency of HBV-PreS1/S2-specific, intracellularcytokine-producing T cells after vaccination of the macaques, peripheralblood mononuclear cells (PBMCs) were isolated from heparinized bloodsamples obtained from immunized macaques at the times before and afterimmunization as noted in Example 3. PBMCs were separated using gradientcentrifugation and stimulated in vitro for 18 hours with HBsAg peptidepools (15mers overlapping by 11 amino acids). HBs-specific T cellssecreting IFN-γ y were detected using paired anti-macaque IFN-γmonoclonal antibodies (U-cytech-BV). Spot forming cells (SFC) wereenumerated using an Immunospot™ Analyzer with CTL Immunospot™ ProfessionSoftware (Cellular Technology Ltd.). Results shown in FIG. 5B are meanSFC per 1 million PBMC time point ±SEM. Tests were run in replicatewells. Net responses shown were determined by subtracting the number ofspots from DMSO stimulated control wells from the same animal.Statistical comparisons between the two groups for each assay wereassessed at each time point using unpaired t test on samples with equalstandard deviation and resuspended in growth media at definedconcentrations (˜1.2 million cells/condition). The number ofHBsAg-specific IFN-γ-producing T cells increased within 14 days afterprimary immunization with G28-8LH-scAb-PreS1-S2-His only and theaddition of the AddaVax™ adjuvant did not increase HBsAg-specific T celllevels.

EXAMPLE 5 Induction in Macaques of HBV-Specific Neutralizing Antibodies(Abs) by G28-8LH-scAb-PreS1-S2-His

To determine the frequency neutralizing antibodies (Abs) to HBV aftervaccination of the macaques, sera were from macaques before (pre-bleed)and 14 days after the second immunization as noted in Example 3. HBVparticles were obtained from the culture supernatants of HepAD38 cellsas an HBV-productive cell line. For HBV infection, HepG2 liver cellsexpressing the NTCP receptor for HBV (HepG2-hNTCP cells) were seeded in60-mm dishes or 6-well plates coated with collagen type 1. After oneday, cells were inoculated with HBV virions at 10³ genome equivalents(Geq) per cell in completed DMEM containing 4% polyethylene glycol (PEG)8000 for 16h. Then, cells were maintained in completed DMEM containing2.5% DMSO for additional days. For the virus neutralizing experiment,the sera being tested for neutralizing Abs were added during theinoculation (16 h) as indicated in FIG. 6A.

For analysis of HBV cccDNAs, viral cccDNAs were isolated with the HirtExtraction Method, for protein-free DNA extraction from HBV-infectedcells. Briefly, cells from 60-mm dishes were lysed in 1 ml of lysisbuffer containing 50 mM Tris-HCI (pH 7.4), 150 mM NaCl, 10 mM EDTA, and1% SDS. After 1 h of incubation at room temperature, the lysates weretransferred into a 2-ml tube, and this step was followed by the additionof 0.25 ml of 2.5 M KCl, then incubation at 4° C. overnight. The lysateswere clarified by centrifugation and extracted with phenol-chloroform.DNA was precipitated with isopropanol overnight and dissolved inNuclease-free water. The extracted DNA was treated with Plasmid-SafeATP-dependent Dnase for southern blot analysis or T5 exonuclease forreal-time PCR. For real-time PCR, total DNAs were purified from infectedcells using DNeasy™ Blood & Tissue Kit (Qiagen). cccDNA levels wereexpressed as a normalized ratio to mitochondrial DNA, and cccDNA weredetected using specific PCR primers.

The sera tested for neutralizing Ab activity included the pre-bleedcontrols (1:1000 dilution) for each animal and sera obtained fromimmunized macaques day 14 after a second immunization. The immune serawere tested for neutralizing Ab activity at either a 1:300 dilution (D),a 1:1000 D or a 1:3000 D. Three sera from immunized macaques (day 14boost) had neutralizing Ab activity that prevented HBV from expressingcccDNA in hepatocytes in vitro, two animals from group 1, and one fromgroup 2 (FIG. 6B). Group 1: G28-8LH-scAb-PreS1-S2-His (300 ug) MonkeyID: A16157, A16159, A16160. Group 2: G28-8LH-scAb-PreS1-S2-His (300 ug)+AddaVax (100 μg) Monkey ID: A16155, A16158, A16168

LITERATURE

-   1. Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J    Hepatol. 2016. 64:S71-83.-   2. Chappell C P, Giltiay N V, Dresch C, Clark E A. Controlling    immune responses by targeting antigens to dendritic cell subsets and    B cells. Int Immunol. 2014. 26:3-11.-   3. Kim H. N., et al., Hepatitis B vaccination in HIV-infected    adults: current evidence, recommendations and practical    considerations. International journal of STD & AIDS, 2009.-   4. Kubba, A. K., et al., Non-responders to hepatitis B vaccination:    a review. Communicable disease and public health/PHLS, 2003.    6:106-12.-   5.Ott, J. J., et al., Global epidemiology of hepatitis B virus    infection: new estimates of age-specific HBcAg seroprevalence and    endemicity. Vaccine 2012. 30:2212-9.-   6. Weinbaum C M, Williams I, Mast E E, et al. Recommendations for    identification and public health management of persons with chronic    hepatitis B virus infection. Centers for Disease Control and    Prevention (CDC). MMWR Recomm Rep. 2008. 57(RR-8):1-20.-   7. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of    hepatitis B virus infection in the United States in the era of    vaccination. J Infect Dis. 2010. 202:192-201.-   8. Mitchell T, Armstrong G L, Hu D J, Wasley A, Painter J A. The    increasing burden of imported chronic hepatitis B-United States,    1974-2008. PLoS One. 2011. 6:e27717.-   9. Hepatitis B vaccines. Releve epidemiologique hebdomadaire/Section    d′hygiene du Secretariat de la Societe des Nations=Weekly    epidemiological record/Health Section of the Secretariat of the    League of Nations, 2004. 79:255-63.-   10. Perz J F et al., The contributions of hepatitis B virus and    hepatitis C virus infections to cirrhosis and primary liver cancer    worldwide. J Hepatol 2006. 45:529-38.-   11. Lavanchy, D., Hepatitis B virus epidemiology, disease burden,    treatment, and current and emerging prevention and control measures.    J Viral Hep 2004. 11:97-107.-   12. Kim W R, Epidemiology of hepatitis B in the United States.    Hepatology, 2009. 49: S28-34.-   13. Wang L, Zou Z Q, Liu C X, Liu X Z. Immunotherapeutic    interventions in chronic hepatitis B virus infection: a review. J    Immunol Methods. 2014 May;407:1-8.-   14. Thai H, Campo D S, Lara J, et al. Convergence and coevolution of    hepatitis B virus drug resistance. Nat Commun. 2012. 3:789.-   15. Menendez-Arias L, Alvarez M, Pacheco B. Nucleoside/nucleotide    analog inhibitors of hepatitis B virus polymerase: mechanism of    action and resistance. Curr Opin Virol. 2014. 8C:1-9.-   16. Wiegand J, van Bornmel F, Berg T, Management of chronic    hepatitis B: status and challenges beyond treatment guidelines.    Semin Liver Dis 2010;30:361-377.-   17. Luckhaupt S E, Calvert G M. Deaths due to bloodborne infections    and their sequelae among health-care workers. Am J Ind Med. 2008.    51:812-24.-   18. Beck, J. and M. Nassal, Hepatitis B virus replication. World J    Gastroenterol WJG, 2007. 13:48-64.-   19. Bruss V. Hepatitis B virus morphogenesis. World J    Gastroenterol. 2007. 13:65-73.-   20. Gerlich W H. Prophylactic vaccination against hepatitis B:    achievements, challenges and perspectives. Med Microbiol    lmmunol. 2015. 204:39-55.-   21. Eng N F, Bhardwaj N, Mulligan R, Diaz-Mitoma F. The potential of    1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™. Hum Vaccin    Immunother. 2013. 9:1661-72.-   22. Jilg W. Novel hepatitis B vaccines. Vaccine. 1998. 16    Suppl:S65-8.-   23. Madalinski K, Sylvan S P, Hellstrom U, Mikolajewicz J,    Zembrzuska-Sadkowska E, Piontek E. Antibody responses to preS    components after immunization of children with low doses of BioHepB.    Vaccine. 2001 Oct 12; 20(1-2):92-7.-   24. Rendi-Wagner P, Shouval D, Genton B, et al. Comparative    immunogenicity of a PreS/S hepatitis B vaccine in non- and low    responders to conventional vaccine. Vaccine. 2006. 24:2781-9.-   25. Ni Y, Lempp F A, Mehrle S, et al. Hepatitis B and D viruses    exploit sodium taurocholate co-transporting polypeptide for    species-specific entry into hepatocytes. Gastroenterology. 2014    April; 146(4):1070-83.-   26. Li W. NTCP is receptor for HBV The hepatitis B virus receptor.    Annu Rev Cell Dev Biol. 2015; 31:125-47.-   27. Chi SW, Kim J. Yi GS, Hong HJ, Ryu SE. Broadly neutralizing    anti-HBV antibody binds to non-epitope regions of preS1. FEBS    Lett. 2009. 583:3095-100.-   28. Ferrari C, Penna A, Bertoletti A et al. The preS1 antigen of    hepatitis B virus is highly immunogenic at the T cell level in man.    J Clin Invest. 1989. 84:1314-9.-   29. Krawczyk A, Ludwig C, Jochum C et al. Induction of a robust T-    and B-cell immune response in non- and low-responders to    conventional vaccination against hepatitis B by using a third    generation PreS/S vaccine.-   Vaccine. 2014. 32:5077-82.-   30. Dion S, Bourgine M, Godon O, Levillayer F, Michel M L.    Adeno-associated virus-mediated gene transfer leads to persistent    hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1    molecules. J Virol. 2013 May; 87(10):5554-63.-   31. Bian Y, Zhang Z, Sun Z et al. Vaccines Targeting PreS1 Domain    Overcome Immune Tolerance in HBV Carrier Mice. Hepatology. 2017    Apr. 26. doi: 10.1002/hep.29239. [Epub ahead of print]-   32. Valentine M A, Clark E A, Shu G L, Norris N A, Ledbetter J A.    Antibody to a novel 95-kDa surface glycoprotein on human B cells    induces calcium mobilization and B cell activation. J Immunol. 1988.    140:4071-8.-   34. Miyake, K., et al., Murine B cell proliferation and protection    from apoptosis with an antibody against a 105-kD molecule:    unresponsiveness of X-linked immunodeficient B cells. J Exp    Med 1994. 180:1217-24.-   34. Miyake, K., et al., RP105, a novel B cell surface molecule    implicated in B cell activation, is a member of the leucine-rich    repeat protein family. J Immunol 1995. 154:3333-40.-   35. Alving C R, Peachman K K, Rao M, Reed S G. Adjuvants for human    vaccines. Curr Opin Immunol. 2012. 24:310-5.-   36. Shimazu, R., et al., MD-2, a molecule that confers    lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp    Med 1999. 189:1777-82.-   37.Hebeis, B., et al., Vav proteins are required for B-lymphocyte    responses to LPS. Blood, 2005. 106:635-40.-   38. Hebeis, B. J., et al., Activation of virus-specific memory B    cells in the absence of T cell help. J Exp Med 2004. 199:593-602.-   39. Yazawa, N., et al., CD19 regulates innate immunity by the    toll-like receptor RP105 signaling in B lymphocytes. Blood, 2003.    102:1374-80.-   40. Chaplin, J. W., et al., Anti-CD180 (RP105) activates B cells to    rapidly produce polyclonal lg via a T cell and MyD88-independent    pathway. J Immunol, 2011. 187:4199-209.-   41. Schultz T E, Blumenthal A. The RP105/MD-1 complex: molecular    signaling mechanisms and pathophysiological implications. J Leukoc    Biol. 2017 January; 101(1):183-192.-   42. Ohto U, Miyake K, Shimizu T. Crystal structures of mouse and    human RP105/MD-1 complexes reveal unique dimer organization of the    toll-like receptor family. J Mol Biol. 2011 Nov. 4; 413(4):815-25.-   43. Yoon S I, Hong M, Wilson I A. An unusual dimeric structure and    assembly for TLR4 regulator RP105-MD-1. Nat Struct Mol Biol. 2011    Aug. 21; 18(9):1028-35.-   45. Chaplin J W, Chappell C P, Clark E A. Targeting antigens to    CD180 rapidly induces antigen-specific IgG, affinity maturation and    immunologic memory. 2013. J Exp Med 210:2135-46.-   46. Ramos, H. J. and M. Gale, Jr., RIG-I like receptors and their    signaling crosstalk in the regulation of antiviral immunity. Curr    Opin Virol, 2011. 1:67-76.-   47. Maxon E R, Siegrist C A. The next decade of vaccines: societal    and scientific challenges. Lancet. 2011. 378:348-59.-   48. Liang Y et al., Predictors of relapse in chronic hepatitis B    after discontinuation of anti-viral therapy. Aliment Pharmacol    Ther, 2011. 34:344-52.-   49. Suthar M S, Diamond M S, Gale M, Jr. West Nile virus infection    and immunity. 2013. Nat Rev Microbiol 11:115-128.-   50. Coffman R L, Sher A, Seder R A. Vaccine adjuvants: putting    innate immunity to work. Immunity. 2010. 33:492-503.-   51. Clark E A, Shu G L, LUscher B, Draves K E, Banchereau J,    Ledbetter J A, Valentine M A. Activation of human B cells.    Comparison of the signal transduced by IL-4 to four different    competence signals. J Immunol. 1989. 143:3873-80.-   Loudon P T, Yager E J, Lynch D T, Narendran A, Stagnar C, Franchini    A M, Fuller J T, White P A, Nyuandi J, Wiley C A, Murphey-Corb M,    Fuller D H. GM-CSF increases mucosal and systemic immunogenicity of    an H1 N1 influenza DNA vaccine administered into the epidermis of    non-human primates. PLoS One. 2010. 5:e11021.-   Toita R, Kawano T, Kang J H, Murata M. Applications of human    hepatitis B virus preS domain in bio- and nanotechnology. World J    Gastroenterol. 2015 Jun. 28; 21(24):7400-11. Chen Y, Bai Y, Guo X,    Wang W, et al. Selection of affinity-improved neutralizing human    scFv against HBV PreS1 from CDR3 VH/VL mutant library. Biologicals.    2016 July; 44(4):271-5.

1. A composition, comprising: (a) CD180 binding ligand; and (b) aHepatitis B antigen selected from the group consisting of a Hepatitis Bvirus pre-S1 and/or pre-S2 region of the HBV envelope protein(HBVpreS1/S2Ag), L-HBsAg, M-HBsAg, S-HBsAg, or antigenic fragments ormutants thereof, wherein the Hepatitis B antigen is attached to theCD180 binding ligand.
 2. The composition of claim 1, wherein the CD180binding ligand is an anti-CD180 antibody or antibody fragment, such asan anti-CD180 monoclonal antibody, a single domain anti-CD180 monoclonalantibody, an anti-CD180 single chain antibody, or a fragment thereof. 3.The composition of claim 1, wherein the CD180 binding ligand comprises asingle chain (sc) recombinant protein, wherein the sc recombinantprotein comprises: (i) a variable heavy (VH) chain region of ananti-CD180 antibody; and (ii) a variable light (VL) chain region of ananti-CD180 antibody.
 4. The composition of claim 3, wherein the VH andVL chain regions are from an anti-human CD180 antibody, such as ananti-human CD180 monoclonal antibody.
 5. The composition of claim 3,wherein the sc recombinant protein does not include any otherimmunoglobulin domains (i.e., scFv), such as a CD180scFv recombinantlyexpressed with an Fc fragment.
 6. The composition of claim 3, whereinthe sc recombinant protein further comprises: (iii) CH2 and CH3 domainsfrom an immunoglobulin (Ig), such as a human Ig, or functional mutantsthereof, wherein the CH2 and CH3 domains are located C-terminal to theVH and VL domains.
 7. The composition of claim 6, wherein the screcombinant protein comprises CH2 and CH3 domains from IgG1, such ashuman IgG1, or functional mutants thereof.
 8. The composition of claim1, wherein the CD180 binding ligand comprises a single domain (sd)recombinant protein, wherein the sd recombinant protein comprises avariable heavy (VHH) chain region of an anti-CD180 antibody derived froma camelid species.
 9. The composition of claim 1, wherein the HepatitisB antigen comprises both preS1 and S2 HBVpreS1/S2Ag regions, orantigenic fragment or mutant thereof.
 10. The composition of claim 3,wherein the Hepatitis B antigen or antigenic fragment or mutant thereof,is located at the N-terminus or the C-terminus of the sc recombinantprotein or the sd recombinant protein.
 11. The composition of claim 3,wherein the CD180 binding ligand is selected from the group consistingof: (a) CD180 VLVH single-chain antibody (CD180LH-scAb); (b) CD180 VHVLsingle-chain antibody (CD180HL-scAb); (c) CD180 VLVH single-chain Fv(CD180LH-scFv); (d) CD180 VHVL single-chain Fv (CD180HL-scFv).
 12. Thecomposition of claim 1, wherein the Hepatitis B antigen comprises apolypeptide having at least 90% identity to the amino acid selected fromthe group consisting of (a) HBV-PreS1-PreS2, (b) HBV-PreS1, (c)HBV-PreS2, (d) HBV-L-HBsAg, (e) HBV-M-HBsAg, (f) HBV-S-HBsAg; and (g) apolypeptide having the amino acid sequence selected from the groupconsisting of SEQ ID NOS:1-66.
 13. The composition of claim 1, whereinthe Hepatitis B antigen comprises a polypeptide having the amino acidselected from the group consisting of: (a) HBV-PreS1-PreS2, (b)HBV-PreS1, (c) HBV-PreS2, (d) HBV-L-HBsAg, (e) HBV-M-HBsAg, (f)HBV-S-HBsAg; or. (g) a polypeptide having an amino acid sequenceselected from the group consisting of SEQ ID NOS:1-66.
 14. Thecomposition of claim 1, comprising a polypeptide having at least 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to theamino acid sequence of SEQ ID NO:67.
 15. The composition of claim 1,wherein the CD180 binding ligand competes for binding to CD180 withmonoclonal antibody G28-8 or MHR73-11. 16.-18. (canceled)
 19. Anisolated nucleic acid encoding the composition of claim
 1. 20. Anexpression vector comprising the isolated nucleic acid of claim 19operatively linked to a suitable control sequence.
 21. A recombinanthost cell comprising the expression vector of claim
 20. 22. Apharmaceutical composition, comprising (a) the composition claim 1; and(b) a pharmaceutically acceptable carrier.
 23. A method for treating orlimiting the development of a hepatitis-B virus (HBV)-related disorder,comprising administering to an individual in need thereof an amounteffective to treat or limit development of the HBV-related disorder ofthe composition of claim 1, or pharmaceutically acceptable saltsthereof. 24.-28. (canceled)